Clinical Trials Logo

Arthritis, Psoriatic clinical trials

View clinical trials related to Arthritis, Psoriatic.

Filter by:

NCT ID: NCT05086042 Completed - Psoriatic Arthritis Clinical Trials

Carpal Tunnel Syndrome in Patients With Psoriatic Arthritis; Ultrasonography and Magnetic Resonance Imaging Findings

Start date: March 15, 2019
Phase:
Study type: Observational

This study aimed to investigate relationship between CTS diagnosis with electrodiagnostic studies and median nerve's cross-sectional area measered by US and MRI in PsA patients.

NCT ID: NCT05086029 Completed - Psoriatic Arthritis Clinical Trials

Carpal Tunnel Syndrome in Patients With Psoriatic Arthritis

Start date: March 20, 2019
Phase:
Study type: Observational

This study aimed to investigate median nerve hypervasculatitation in psoriatic arthritis (PsA) patients with CTS or without CTS by using SMI, then compare them with normal people.

NCT ID: NCT05083182 Not yet recruiting - Arthritis, Juvenile Clinical Trials

A Study of Ustekinumab in Pediatric Participants With Active Juvenile Psoriatic Arthritis

PSUMMIT-Jr
Start date: October 8, 2021
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the pharmacokinetics (PK) and efficacy of ustekinumab in juvenile psoriatic arthritis (jPsA).

NCT ID: NCT05083078 Not yet recruiting - Healthy Clinical Trials

A Study of Guselkumab and Risankizumab in Healthy Participants and Participants With Psoriatic Arthritis

Start date: October 27, 2021
Phase: Phase 1
Study type: Interventional

The purpose of this study is to assess the tissue distribution of guselkumab and risankizumab in healthy participants (Part 1) and psoriatic arthritis (PsA) participants (Part 2).

NCT ID: NCT05082805 Active, not recruiting - Clinical trials for Rheumatoid Arthritis

Therapeutic Strategy Associated With bDMARDs or tsDMARDs in Rheumatoid Arthritis and Psoriatic Arthritis

STRATEGE2
Start date: February 25, 2019
Phase:
Study type: Observational

This is a longitudinal, observational, prospective, multicentre study conducted in France, among a representative sample of rheumatology doctors. The aim of this study is to describe in real life the therapeutic strategy when faced with a patient with rheumatoid arthritis (RA) or psoriatic arthritis (PsA) who requires initiation of treatment with biotherapy or targeted therapy. The evolution of the disease and the possible therapeutic adaptations will then be followed for 2 years.

NCT ID: NCT05080218 Not yet recruiting - Clinical trials for Rheumatoid Arthritis

COVID-19 VaccinE Response in Rheumatology Patients

COVER
Start date: October 2021
Phase: Phase 4
Study type: Interventional

The COVID-19 VaccinE Response in Rheumatology patients (COVER) study is a multicenter randomized controlled trial designed to evaluate the efficacy and safety of a mRNA COVID-19 vaccine supplemental dose (booster) in patients with autoimmune conditions and to evaluate the impact of different immunomodulatory therapies on vaccine response. We propose to recruit up to 1000- patients with autoimmune conditions who have a completed 2-dose regime of mRNA COVID-19 vaccine (>28 days prior) and who are planning to receive an additional dose of mRNA COVID-19 vaccine (i.e., booster). Participants in this study will be men and women 18 years and older with confirmed rheumatic disease, including psoriatic arthritis (PsA), axial spondyloarthritis (SpA) and rheumatoid arthritis (RA) who express a decision to receive the mRNA vaccination booster within 30 days post enrollment. A primary obective of this study is to test the hypothesis that holding certain medications for a brief period of time around the time of COVID-19 vaccination might improve the response to the vaccine while not unduly having safety concerns with respect to the effects of their disease. During the study, participants using the immunomodulatory therapies described outlined in protocol will be randomized to temporarily hold (for 2 weeks) versus continue after they receive the COVID-19 vaccine supplemental dose. Patients who temporarily stop one of their medications for their autoimmune inflammatory disease may be at increased risk of flares of their autoimmune condition. If these occur, they are expected to occur within 2 - 4 weeks of treatment interruption. Detailed protocol outlines the hold schedules for the therapies to be randomized in this study.

NCT ID: NCT05075343 Completed - Psoriatic Arthritis Clinical Trials

Effect of Custom Foot Orthoses in Patients With Psoriatic Arthritis

Start date: July 1, 2019
Phase: N/A
Study type: Interventional

Foot involvement is a major concern in psoriatic arthritis (PsA). The patients could experience severe levels of foot pain and disability and reduced mobility and quality of life. Previous studies showed that the use of Custom foot orthoses (CFO) was effective to improve foot pain and perceived disability in patients with foot disease associated with rheumatoid arthritis. However, there are no records in the literature on the effectiveness of CFO in PsA patients. Therefore, our objective was o explore the effects of CFO on foot pain, foot function, gait spatiotemporal parameters (STP), and ambulatory physical activity (APA) in PsA patients with foot involvement. In this pre-experimental exploratory study, 22 PsA patients having stable medication in the last 3 months preceding the recruitment were recruited. All the patients wore functional CFO designed by an experimented podiatrist during a 7-week period. Foot and lower limb pain and foot function were measured at baseline (T0) and after the 7-week period using the numerical rating scale (NRS) and the foot function index (FFI), respectively. Gait function was assessed by recording spatiotemporal parameters (STPs) during a 10-meter walk test using an instrumented gait analysis system (Mobility Lab) at T0 and T7. Freeliving walking activities (step count, freeliving cadence, time spent in different ambulatory physical activity (APA) intensities) at T0 and T7 were recorded over 7 days using accelerometer data collected from an instrumented sock worn by the participants during waking hours.

NCT ID: NCT05071664 Not yet recruiting - Clinical trials for Arthritis, Psoriatic

A Study of Guselkumab and Golimumab Combination Therapy in Participants With Active Psoriatic Arthritis

AFFINITY
Start date: October 15, 2021
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the efficacy of guselkumab plus golimumab combination treatment in participants with active psoriatic arthritis (PsA) and inadequate response (IR) to a prior anti-tumor necrosis factor-alpha (anti-TNF-alpha) therapy by assessing clinical response compared with guselkumab monotherapy.

NCT ID: NCT05055934 Not yet recruiting - Psoriatic Arthritis Clinical Trials

Study of the Effectiveness and Safety of SHR-1314 for Psoriatic Arthritis

Start date: September 30, 2021
Phase: Phase 2
Study type: Interventional

This study is a randomized, double-blind, multicenter, placebo-controlled Phase II clinical study, consisting of a 4-week screening period, a 12-week core treatment period, a 12-week maintenance treatment period, and an 8-week safety follow-up period. It is planned to include 111 adult subjects with psoriatic arthritis.

NCT ID: NCT05051943 Recruiting - Clinical trials for Rheumatoid Arthritis

A Prospective Observational Study of the Real-world Use of an Adalimumab Biosimilar and Evaluation of Nutritional Status on the Therapeutic Response

OPALE
Start date: September 28, 2020
Phase:
Study type: Observational

The aim of the study is to describe the real-world profile of patients treated with adalimumab FK in gastroenterology, dermatology or rheumatology in order to evaluate in this population the predictive factors of therapeutic response (in particular nutritional status) and generate hypothesis between nutritional status and therapeutic response.